Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ascentage-Innovent NDA Accepted for Priority Review of Chronic Myeloid Leukemia Therapy

publication date: Jul 20, 2022

Ascentage and Innovent reported that their partnered third-gen TKI was accepted for China NDA review under Priority rules following a Phase II trial in patients with chronic-phase chronic myeloid leukemia (CML-CP). The NDA supports full approval of olverembatinib in patients with CML-CP who are resistant or intolerant of first- and second-gen tyrosine kinase inhibitors. In July 2021, Ascentage and Innovent partnered joint commercialization of olverembatinib in China in a three-part, $245 million deal. Both Innovent and Ascentage are headquartered in Suzhou. More details....

Stock Symbols: (HK: 68550) (HK: 01801)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital